Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Sherman D. Baker

Internal Medicine
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sherman Baker is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Baker is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Baker is currently accepting new patients.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1250 E Marshall St, Internal Medicine, Richmond, VA 23298
Call: 804-828-9723

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
View 5 Less Clinical Trials

14 Total Publications

Spot size measurement of a deuterium-tritium dense plasma focus using neutron radiography.
Spot size measurement of a deuterium-tritium dense plasma focus using neutron radiography.
Journal: The Review of scientific instruments
Published: November 14, 2023
View All 14 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Brian J. Foster
Internal Medicine
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Brian J. Foster
Internal Medicine

Bon Secours Memorial Regional Medical Center LLC

4620 S Laburnum Ave, 
Richmond, VA 
 (4.2 miles away)
804-226-2444
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Foster is a primary care provider, practicing in Internal Medicine in Richmond, Virginia. Dr. Foster is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Dementia, Glucocorticoid-Remediable Aldosteronism, Familial Hypertension, Cardiac Ablation, and Hip Replacement. Dr. Foster is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Craig P. Prokos
Internal Medicine
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Craig P. Prokos
Internal Medicine

Universal Health Corporation

200 Weaver Ave, 
Emporia, VA 
 (58.4 miles away)
540-814-5344
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Prokos is a primary care provider, practicing in Internal Medicine in Emporia, Virginia. Dr. Prokos is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Glucocorticoid-Remediable Aldosteronism, Vertebroplasty, and Bone Graft. Dr. Prokos is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. James P. Majdic
Family Medicine | Internal Medicine
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. James P. Majdic
Family Medicine | Internal Medicine

Sentara Medical Group

4374 New Town Ave, Suite 102, 
Williamsburg, VA 
 (42.0 miles away)
757-259-6770
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Majdic is a primary care provider, practicing in Family Medicine and Internal Medicine in Williamsburg, Virginia. Dr. Majdic is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Sinusitis, and Hip Replacement. Dr. Majdic is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baker's expertise for a condition
ConditionClose
    • Distinguished
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Baker is
      Distinguished
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Baker is
      Distinguished
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Lung Adenocarcinoma
      Dr. Baker is
      Distinguished
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Lung Cancer
      Dr. Baker is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Non-Small Cell Lung Cancer (NSCLC)
      Dr. Baker is
      Distinguished
      . Learn about Non-Small Cell Lung Cancer (NSCLC).
      See more Non-Small Cell Lung Cancer (NSCLC) experts
    • Small Cell Lung Cancer (SCLC)
      Dr. Baker is
      Distinguished
      . Learn about Small Cell Lung Cancer (SCLC).
      See more Small Cell Lung Cancer (SCLC) experts
    View All 7 Distinguished Conditions
    • Advanced
    • Hairy Cell Leukemia (HCL)
      Dr. Baker is
      Advanced
      . Learn about Hairy Cell Leukemia (HCL).
      See more Hairy Cell Leukemia (HCL) experts
    • Mediastinal Tumor
      Dr. Baker is
      Advanced
      . Learn about Mediastinal Tumor.
      See more Mediastinal Tumor experts
    • Neuroendocrine Tumor
      Dr. Baker is
      Advanced
      . Learn about Neuroendocrine Tumor.
      See more Neuroendocrine Tumor experts
    • Non-Hodgkin Lymphoma
      Dr. Baker is
      Advanced
      . Learn about Non-Hodgkin Lymphoma.
      See more Non-Hodgkin Lymphoma experts
    • Reticuloendotheliosis
      Dr. Baker is
      Advanced
      . Learn about Reticuloendotheliosis.
      See more Reticuloendotheliosis experts
    • Thymic Epithelial Tumor
      Dr. Baker is
      Advanced
      . Learn about Thymic Epithelial Tumor.
      See more Thymic Epithelial Tumor experts
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Baker is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Baker is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Baker is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Alpha-1 Antitrypsin Deficiency (AATD)
      Dr. Baker is
      Experienced
      . Learn about Alpha-1 Antitrypsin Deficiency (AATD).
      See more Alpha-1 Antitrypsin Deficiency (AATD) experts
    • Anaplastic Thyroid Cancer
      Dr. Baker is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Anemia
      Dr. Baker is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved